PARLIAMENTARY WRITTEN QUESTION
NHS: Remdesivir (7 July 2020)
Question Asked
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of NHS access to remdesivir; and if he will make a statement.
Asked by:
Ed Davey (Liberal Democrat)
Asked by:
Ed Davey (Liberal Democrat)
Answer
Remdesivir has been available to National Health Service patients with COVID-19 as part of clinical trials and through the Early Access to Medicines Scheme. Remdesivir has now been granted a conditional marketing authorisation for use in patients with COVID-19 and NHS England and NHS Improvement have published an interim commissioning policy, which states that NHS patients will be eligible for treatment in accordance with its licence. The NHS has sufficient stock for patients who need it.
Answered by:
Jo Churchill (Conservative)
21 July 2020
Contains Parliamentary information licensed under the Open Parliament Licence v3.0.